Form 4: Revolution Medicines Director Barbara Weber Reports Acquisition of Shares and Stock Options

Director Barbara Weber reports acquiring 4,800 shares of common stock and stock options for 16,700 shares in Revolution Medicines.

Summary

• On June 20, 2024, Barbara Weber, a director of Revolution Medicines, Inc., acquired 4,800 shares of common stock.
• These shares were acquired at a price of $0.
• Following this transaction, Weber directly owns 20,625 shares of common stock, which includes 4,800 restricted stock units.
• Weber also acquired stock options for 16,700 shares with an exercise price of $37.54, expiring on June 19, 2034.
• These options vest on the earlier of June 20, 2025, or immediately before the next Annual Meeting, contingent on continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions. The acquisition of shares and options by a director can be seen as a mildly positive signal, but it's not strong enough to significantly skew the sentiment.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is contingent on continued service, suggesting an ongoing commitment from the director.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as insider buying is often viewed favorably.

Key Dates